Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing molecular mechanisms and signaling pathways without systematic meta-analysis.
PubMed 41573745 · doi:10.3389/fmolb.2025.1729904
What was done
This narrative review synthesized multi-omics data, cell and animal functional experiment findings, and clinical literature to describe the structural modifications, signaling pathways, and multi-organ mechanisms of action of oral glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus.
What was found
The abstract reports no quantitative clinical metrics, effect sizes, or trial numbers. It reports mechanistic pathways: structural modifications confer resistance to DPP-4 degradation; activation of the Gs/cAMP/PKA/EPAC axis mediates glucose-dependent insulin secretion alongside glucagon suppression; IL-6/STAT3 signaling enhances adipose thermogenesis; and pathways including AMPK and PI3K-Akt mediate beta-cell protection, hepatic lipid regulation, and renal sodium excretion.
Why it matters
It provides a consolidated summary of the molecular signaling networks through which oral GLP-1 receptor agonists exert glycemic control, weight loss, and organ-protective effects.
Limits
The abstract describes a narrative mechanistic review without systematic search protocols, quality grading, pooled quantitative clinical data, or sample size details.
Cited by
- supports GLP-1 receptor agonists stimulate insulin secretion upon eating to clear glucose from the blood and improve insulin sensitivity.